Benjamin Ellezam

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6566715/publications.pdf

Version: 2024-02-01

36	2,449	394421	395702
papers	citations	19	33
		h-index	g-index

38	38	38	4451
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report. BMC Rheumatology, 2022, 6, 11.	1.6	1
2	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients. Current Oncology, 2021, 28, 346-366.	2.2	27
3	Capillary basement membrane reduplication in myositis patients with mild clinical features of systemic sclerosis supports the concept of â€˜scleromyositisâ€™. Acta Neuropathologica, 2021, 142, 395-397.	7.7	7
4	Histopathological features of systemic sclerosis-associated myopathy: A scoping review. Autoimmunity Reviews, 2021, 20, 102851.	5.8	17
5	Corneal imaging with optical coherence tomography assisting the diagnosis of mucolipidosis type IV. Canadian Journal of Ophthalmology, 2021, 56, e120-e121.	0.7	0
6	French-Canadian families from Saguenay-Lac-Saint-Jean: a new founder population for APECED. Endocrine, 2021, , 1.	2.3	1
7	Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Research and Therapy, 2020, 22, 5.	3.5	48
8	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell, 2020, 183, 1617-1633.e22.	28.9	93
9	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. Neuro-Oncology, 2020, 22, iii327-iii328.	1.2	0
10	Multisystem Proteinopathy Associated with a VCP G156S Mutation in a French Canadian Family. Canadian Journal of Neurological Sciences, 2020, 47, 412-415.	0.5	7
11	Novel Recessive TNNT1 Congenital Coreâ€Rod Myopathy in French Canadians. Annals of Neurology, 2020, 87, 568-583.	5.3	19
12	CTNI-67. EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN EXPANDED DATASET. Neuro-Oncology, 2020, 22, ii58-ii58.	1.2	2
13	Statin-associated anti-HMGCR immune-mediated necrotizing myopathy with dermatomyositis-like features: A case report. SAGE Open Medical Case Reports, 2020, 8, 2050313X2098412.	0.3	3
14	LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. Neuro-Oncology, 2020, 22, iii371-iii371.	1.2	1
15	CTNI-24. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. Neuro-Oncology, 2020, 22, ii47-ii47.	1.2	0
16	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell, 2019, 36, 51-67.e7.	16.8	69
17	Astrocytes in the Pathogenesis of Multiple Sclerosis: An In Situ MicroRNA Study. Journal of Neuropathology and Experimental Neurology, 2019, 78, 1130-1146.	1.7	13
18	Biallelic variants in the transcription factor PAX7 are a new genetic cause of myopathy. Genetics in Medicine, 2019, 21, 2521-2531.	2.4	25

#	Article	IF	Citations
19	Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas. Cancer Cell, 2019, 35, 782-797.e8.	16.8	143
20	Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers. JAMA Network Open, 2019, 2, e192906.	5.9	36
21	H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis. Nature Communications, 2019, 10, 1262.	12.8	215
22	Stalled developmental programs at the root of pediatric brain tumors. Nature Genetics, 2019, 51, 1702-1713.	21.4	136
23	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer, 2019, 19, 1250.	2.6	93
24	Mucolipidosis type IV in a child. Journal of AAPOS, 2018, 22, 469-471.	0.3	6
25	Trametinib for progressive pediatric low-grade gliomas. Journal of Neuro-Oncology, 2018, 140, 435-444.	2.9	75
26	Brainstem angiocentric gliomas with MYBâ€“QKI rearrangements. Acta Neuropathologica, 2017, 134, 667-669.	7.7	20
27	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications, 2016, 7, 11185.	12.8	197
28	Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. Acta Neuropathologica, 2016, 131, 847-863.	7.7	143
29	Transarterial Onyx Embolization of an Orbital Solitary Fibrous Tumor. Ocular Oncology and Pathology, 2015, 1, 98-102.	1.0	12
30	Adult brainstem gliomas: Correlation of clinical and molecular features. Journal of the Neurological Sciences, 2015, 353, 92-97.	0.6	44
31	SYK is a target of lymphocyte-derived microparticles in the induction of apoptosis of human retinoblastoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 1613-1622.	4.9	9
32	Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathologica, 2014, 128, 733-741.	7.7	116
33	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genetics, 2014, 46, 462-466.	21.4	381
34	Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nature Medicine, 2014, 20, 1147-1156.	30.7	380
35	Adult pilocytic astrocytomas: clinical features and molecular analysis. Neuro-Oncology, 2014, 16, 841-847.	1.2	59
36	Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas. Acta Neuropathologica, 2012, 124, 449-451.	7.7	50